Kate Therapeutics
NEWS
Adeno-associated viruses have long been go-to vectors for gene therapies. How AAVs are improving will be among the cell and gene therapy topics to be covered in Baltimore this week.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
IN THE PRESS
JOBS